These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11032369)

  • 1. An in vivo model of hyperacute rejection: characterization and evaluation of the effect of transgenic human complement inhibitors.
    Mora M; Lazzer M; Marsicano G; Mulder LC; Carraresi L; Pieri A; Benanchi A; Grifoni D; Nuti S; Bruzzone P; Comporti M; Cortesini R; Rossini M
    Transgenic Res; 2000 Jun; 9(3):205-13. PubMed ID: 11032369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidneys derived from mice transgenic for human complement blockers are protected in an in vivo model of hyperacute rejection.
    Lazzeri M; Mora M; Mulder LC; Marsicano G; Marinucci G; Boschi M; Bruzzone P; Alfani D; Cortesini R; Rossini M
    J Urol; 1998 Apr; 159(4):1364-9. PubMed ID: 9507885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A human CD46 transgenic pig model system for the study of discordant xenotransplantation.
    Diamond LE; Quinn CM; Martin MJ; Lawson J; Platt JL; Logan JS
    Transplantation; 2001 Jan; 71(1):132-42. PubMed ID: 11211178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejection.
    Yannoutsos N; Ijzermans JN; Harkes C; Bonthuis F; Zhou CY; White D; Marquet RL; Grosveld F
    Genes Cells; 1996 Apr; 1(4):409-19. PubMed ID: 9135084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative roles of hCD46 and hCD55 in the regulation of hyperacute rejection.
    Verbakel CA; Bonthuis F; Eerhart SE; van Dixhoorn M; Grosveld F; Marquet RL; IJzermans JN
    Transplant Proc; 2000 Aug; 32(5):903-4. PubMed ID: 10936266
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression and functional analysis of glycosyl-phosphatidyl inositol-linked CD46 in transgenic mice.
    Shinkel TA; Cowan PJ; Barlow H; Aminian A; Romanella M; Lublin DM; Pearse MJ; d'Apice AJ
    Transplantation; 1998 Dec; 66(11):1401-6. PubMed ID: 9869079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of hyperacute transplant rejection by soluble proteins with the functional domains of CD46 and FcgammaRII.
    Lanteri MB; Powell MS; Christiansen D; Li YQ; Hogarth M; Sandrin MS; Mckenzie IF; Loveland BE
    Transplantation; 2000 Mar; 69(6):1128-36. PubMed ID: 10762218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production and characterization of a pig line transgenic for human membrane cofactor protein.
    Zhou CY; McInnes E; Parsons N; Langford G; Lancaster R; Richards A; Pino-Chavez G; Dos Santos Cruz G; Copeman L; Carrington C; Thompson S
    Xenotransplantation; 2002 May; 9(3):183-90. PubMed ID: 11983016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life-supporting human complement regulator decay accelerating factor transgenic pig liver xenograft maintains the metabolic function and coagulation in the nonhuman primate for up to 8 days.
    Ramirez P; Chavez R; Majado M; Munitiz V; Muñoz A; Hernandez Q; Palenciano CG; Pino-Chavez G; Loba M; Minguela A; Yelamos J; Gago MR; Vizcaino AS; Asensi H; Cayuela MG; Segura B; Marin F; Rubio A; Fuente T; Robles R; Bueno FS; Sansano T; Acosta F; Rodriguez JM; Navarro F; Cabezuelo J; Cozzi E; White DJ; Calne RY; Parrilla P
    Transplantation; 2000 Oct; 70(7):989-98. PubMed ID: 11045632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The control of hyperacute rejection by genetic engineering of the donor species.
    White DJ; Cozzi E; Langford G; Oglesby T; Wang MW; Wright L; Wallwork J
    Eye (Lond); 1995; 9 ( Pt 2)():185-9. PubMed ID: 7556715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic expression in pig hearts of both human decay-accelerating factor and human membrane cofactor protein does not provide an additional benefit to that of human decay-accelerating factor alone in pig-to-baboon xenotransplantation.
    Mañez R; Lopez-Pelaez E; Centeno A; Herrera JM; Juffe A; Domenech N; Harrison R; Schuurman HJ
    Transplantation; 2004 Sep; 78(6):930-3. PubMed ID: 15385816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection.
    Fodor WL; Williams BL; Matis LA; Madri JA; Rollins SA; Knight JW; Velander W; Squinto SP
    Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11153-7. PubMed ID: 7526391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion.
    McCurry KR; Kooyman DL; Diamond LE; Byrne GW; Logan JS; Platt JL
    Transplantation; 1995 Apr; 59(8):1177-82. PubMed ID: 7537395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopathological observations after xenogeneic liver perfusions using donor pigs transgenic for human decay-accelerating factor.
    Pascher A; Poehlein C; Storck M; Prestel R; Mueller-Hoecker J; White DJ; Abendroth D; Hammer C
    Transplantation; 1997 Aug; 64(3):384-91. PubMed ID: 9275100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement.
    White DJ; Oglesby T; Liszewski MK; Tedja I; Hourcade D; Wang MW; Wright L; Wallwork J; Atkinson JP
    Transpl Int; 1992; 5 Suppl 1():S648-50. PubMed ID: 14621899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation.
    Kroshus TJ; Salerno CT; Yeh CG; Higgins PJ; Bolman RM; Dalmasso AP
    Transplantation; 2000 Jun; 69(11):2282-9. PubMed ID: 10868627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of complement regulatory proteins on islets of Langerhans: a comparison between human islets and islets isolated from normal and hDAF transgenic pigs.
    Bennet W; Björkland A; Sundberg B; Brandhorst D; Brendel MD; Richards A; White DJ; Nilsson B; Groth CG; Korsgren O
    Transplantation; 2001 Jul; 72(2):312-9. PubMed ID: 11477359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAF transgenic pig livers are protected from hyperacute rejection during ex vivo perfusion with human blood.
    Luo Y; Levy G; Ding J; Qi J; Chakbrati S; Garcia BM; Phillips MJ; Kumar N; Friend P; Noble L; Macdonald J; Zhong R; Grant D
    Xenotransplantation; 2002 Jan; 9(1):36-44. PubMed ID: 12005103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection.
    Cary N; Moody J; Yannoutsos N; Wallwork J; White D
    Transplant Proc; 1993 Feb; 25(1 Pt 1):400-1. PubMed ID: 7679815
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons.
    Loveland BE; Milland J; Kyriakou P; Thorley BR; Christiansen D; Lanteri MB; Regensburg M; Duffield M; French AJ; Williams L; Baker L; Brandon MR; Xing PX; Kahn D; McKenzie IF
    Xenotransplantation; 2004 Mar; 11(2):171-83. PubMed ID: 14962279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.